Bone marrow transplantation (BMT) has been used for a wide variety of lysosomal storage diseases with encouraging results. We report a 3-year 5-month-old girl with Niemann-Pick type C disease (NPC) who received an allogeneic BMT. The patient presented with repeated lower respiratory tract infections, hepatosplenomegaly, failure to thrive, and developmental delay. Chest computed tomography (CT) revealed diffuse interstitial lung infiltration. Bone marrow and liver biopsies revealed abundant lipid-filled foamy macrophages. Skin fibroblast sphingomyelinase assay revealed partial deficiency. The ability of her skin fibroblasts to esterify cholesterol was very low, and the cells stained brightly for free cholesterol. She received BMT from a healthy HLA-identical male sibling donor at the age of 2 year 6 months. Full engraftment was evidenced by repeated bone marrow sex chromosome studies. Regression of the hepatosplenomegaly, markedly reduced foamy macrophage infiltration in bone marrow, and decreased interstitial lung infiltration was noted 6 months after BMT. Her neurological status, however, deteriorated. Follow-up magnetic resonance image (MRI) revealed progressive, diffuse brain atrophy. We conclude that resolution occurred in the liver, spleen, bone marrow and lung following successful engraftment. Such a response is remarkable since the underlying problem involves a membrane receptor for cholesterol. This positive response might be due to replacement of the monocyte-phagocytic system or it may imply the existence of cross-correction in the NPC membrane receptor defect by BMT approach. Since BMT did not halt the neurological deterioraton, it is unlikely to be an adequate treatment for NPC.
Niemann-Pick type C disease (NPC) is an autosomal recessive storage lipidosis in which fibroblasts exhibit a unique biochemical lesion characterized by delayed and impaired homeostatic responses to exogenous low-density lipoprotein (LDL) cholesterol loading, with lysosomal accumulations of unesterified cholesterol. The diagnosis is established by demonstration of both impaired cholesterol esterification in cultured fibroblasts and a characteristic pattern of intense perinuclear fluorescence after filipin staining.
1-2 NPC is biochemically entirely different and phenotypically distinct from the sphingomyelin lipidoses (type A and type B Niemann-Pick disease 3 ), with which it has traditionally been grouped. The cardinal pathologic features of all forms of NPC are visceral foamy cells and neuronal storage. Foamy cells and sea-blue histiocytes containing accumulations of sphingomyelin and cholesterol are conspicuous in the spleen, tonsils, lymph nodes, liver and lung and usually cause visceromegaly. Most patients with NPC have progressive neurologic disease, although hepatic damage is prominent in certain cases. 4 Both linkage and complementation analyses have shown that at least two separate genes, NPC1 (major locus) and NPC2, induce identical clinical and biochemical phenotypes. 5 The NPC1 gene on chromosome 18q11 was recently cloned by positional cloning and the NPC1 protein is thought to be an integral membrane protein. 6 Specific treatment that will change the natural history of the disease is not yet available. Bone marrow transplantation (BMT) and combined liver and bone marrow transplantation in the C57BL/KsJ murine model of NPC partially reversed tissue storage of cholesterol and sphingomyelin, but did not influence the continued neurologic deterioration. There is no previous report of BMT for human NPC. We report a case of NPC who successfully engrafted after allogeneic BMT.
Case report
In September 1996, a 14-month-old girl was referred for investigation of repeated lower respiratory tract infections, developmental delay, and persistent hepatosplenomegaly. She was born by normal spontaneous vaginal delivery after 39 weeks of gestation with a birth weight 2170 g. Intrauterine growth retardation was noted during pregnancy. No specific problems occurred in the neonatal period except for transient hyperbilirubinemia. At 3 months of age, acute bronchiolitis was noted. Jaundice recurred and hepatosplenomegaly was noted. Liver function tests showed: AST 190 U/l, ALT 104 U/l, total bilirubin 4.9 mg/dl, direct bilirubin 2.7 mg/dl, and alkaline phosphatase 842 U/l. Work up for congenital infection, hepatitis, cytomegalovirus, sepsis and biliary tract disease yielded no positive results. The jaundice subsided 2 months later without any treatment. However, persistent hepatosplenomegaly, delayed developmental milestones and four episodes of acute bronchiolitis without sign of respiratory distress occurred during the first year of life. Initially, physical examination in our hospital revealed hepatosplenomegaly and slightly coarse breathing sounds. Her liver was palpable 4 cm below the right costal margin and spleen 8 cm below the left costal margin. Neurologically, she had mild mental retardation, dysarthria, ataxia, dysmetria, bilateral lower extremity spasticity, and vertical supranuclear ophthalmoplegia. The Babinski sign was positive bilaterally and deep tendon reflex of all extremities was also increased. Laboratory tests revealed: AST 114 U/l, ALT 16 U/l, total bilirubin 0.4 mg/dl, direct bilirubin 0.1 mg/dl, and alkaline phosphatase 374 U/l. The cerebrospinal fluid was acellular with normal protein and glucose levels and without oligoclonal bands. Hematopoietic parameters were within normal limits. Plain chest radiography and high-resolution chest computed tomography (CT) revealed diffuse interstitial lung infiltration ( Figure 1a ). Brain magnetic resonance image (MRI) revealed normal myelination without obvious brain atrophy (Figure 2a) . However, electroencephalography (EEG) showed diffuse cortical dysfunction. Bone marrow and liver biopsies revealed abundant foamy lipid-filled macrophages (Figure 3a) , and the foamy cells were filled with secondary lysosomes containing membranous cytoplasmic bodies of variable sizes resembling concentric lamellated myelin figures on electron microscopic examination ( Figure 4 ). The ability of cultured skin fibroblasts to esterify cholesterol was very low: 3 Ϯ 8 (pmoles cholesterol ester formed/mg protein, normal value: 3432 Ϯ 1729, average Niemann-Pick type C value: 90 Ϯ 140), and the cells stained brightly for free cholesterol using the filipin stain, performed by Dr Adele Cooney at the Developmental Metabolic Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MA, and also by Dr David A Wenger at the Division of Medical Genetics, Jefferson Medical College, Philadelphia, Pensylvania, USA. Sphingomyelinase assay of the cells revealed partial deficiency (40% of normal level). Hence, NPC was confirmed.
Allogeneic BMT with her HLA-identical sibling donor (5-year-old brother, donor blood type O vs recipient blood type B) was performed at 2 years 6 months of age. Evaluation 1 month before transplant showed her body weight to be below the 3rd percentile and both body height and head girth were around 3rd-10th percentile. Liver and spleen were 3 cm and 8 cm below the costal margins, respectively. Developmental regression was noted. There had been no speech development during the past year and even the ability and frequency of voicing repetitive consonant sounds (mama, dada) decreased. She had been able to sit without support and to crawl at 14 months old, but both skills were lost before BMT. Laboratory tests revealed AST 97 U/l, ALT 21 U/l, total bilirubin 0.6 mg/dl, direct bilirubin 0.2 mg/dl, alkaline phosphatase 643 U/l, and a normal hemogram. The conditioning regimen consisted of busulfan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg), followed by cyclophosphamide 60 mg once daily i.v. for 2 days (total dose 120 mg/kg). For prophylaxis of graft-versus-host disease (GVHD), she received cyclosporine 3 mg/kg i.v. daily starting one day before BMT (day −1), and methotrexate (MTX) 15 mg/m 2 on day +1, and MTX 10 mg/m 2 on days +3, +6 and +11. A generalized tonic-clonic seizure occurred on day −3. After a series of investigations including brain CT, electrolytes, electrocardiography, and cerebrospinal fluid studies, no specific etiology was found, and busulfan was considered to be responsible. The seizure was controlled with phenytoin. However, acute neurologic deterioration was noted during this period. She became totally bed ridden, unable to voice repetitive consonant sounds (mama, dada) and spasticity increased, but she could still swallow well, keep her head erect, sit in a chair with her trunk erect, and no head lag. She received Bone marrow aspiration 3 weeks later showed full engraftment as evidenced by sex chromosome studies (all cells were 46 XY male donor type) although many foamy cells could still be seen. One month after BMT, she was discharged in stable clinical condition but with persistent hepatosplenomegaly, and bed-ridden.
Six months after transplantation, her liver and spleen were impalpable. Grade I GVHD developed. Bone marrow aspiration and biopsy still showed complete engraftment with normocellularity. The most striking finding was that the lipid-filled foamy macrophages seen in previous biopsies were not found in most areas (Figure 3b) . Chest CT at 6 and 9 months revealed almost complete resolution of the previous lung infiltrate (Figure 1b) . However, developmental regression progressed after the transplant. She could vocalize when talked to or sung to but there was no ability to imitate speech sounds or repeat consonants. Difficulty with swallowing occurred during these months. She could not keep her head erect or raise her body or maintain a prone position at 45°. She became unable to sit in a chair with her trunk erect. Head lag became obvious during traction pulling to sit. In addition, horizontal supranuclear ophthalmoplegia appeared. The developmental quotient of gross motor, language, fine motor, and personalsocial skills decreased significantly both before and after BMT. The estimated developmental age using the Denver Development Screening Test II was 10-14 months, 10-14 months, 5-8 months, 3-5 months, 2-4 months at chronological ages of 1 year 8 months (1y8m), 2y5m, 2y7m, 2y11m, 3y3m, respectively. EEG showed markedly diffuse cortical dysfunction. Although she had no obvious brain atrophy at the time of BMT, brain MRI 6 months later showed obvious diffuse brain atrophy with decreased thickness of the white matter (Figure 2b ).
Discussion
NPC has heterogeneous clinical manifestations. The classic phenotype is characterized by variable hepatosplenomegaly, vertical supranuclear ophthalmoplegia, progressive ataxia, dystonia, and dementia. The onset is usually in late childhood, and death occurs in the second decade. Other phenotypes include fatal neonatal liver disease, early infantile onset with hypotonia and delayed motor development, and adult variants where psychosis and dementia predominate. 7 There is still no specific treatment for NPC. Treatment strategies to reduce intracellular cholesterol accumulation have been formulated based on the hypothesis that cholesterol is an offending metabolite in NPC. BALB/C mutant mice fed with a low cholesterol diet live twice as long as those given a 2% cholesterol diet. 4 The combination of cholesterol lowering agents including cholestyramine, lovastatin, and nicotinic acid lowered cholesterol by 20% in the liver and blood of NPC patients with minimal sideeffects, but any influence on the rate of neurologic progression is doubtful. 8 Dimethyl sulfoxide (DMSO) has been proved to be an activator of acid sphingomyelinase and to accelerate the intracellular mobilization of LDL-derived cholesterol. It has been known to correct a partial deficiency of acid sphingomyelinase activity in NPC fibroblasts and oral administration of DMSO has brought about clinical improvement including reduction in hepatosplenomegaly and seizure frequency but the progressive clinical course did not change although it appeared to slow down. [9] [10] [11] DMSO may be worth trying in NPC patients.
In the C57BL/KsJ spm/spm murine model of NPC, BMT decreased the accumulation of sphingomyelin and cholesterol quantitatively in the spleen, and the sphingomyelin deposited in the bone marrow was also reduced on histology. On the other hand, neurological involvement was not improved by the graft. 12 Combined liver and bone marrow transplantation in mice partially reversed tissue storage of cholesterol and sphingomyelin, and ameliorated hepatosplenomegaly but did not influence the continued neurologic deterioration and life span. Foamy cells disappeared from bone marrow, liver, spleen, thymus, and lymph nodes, but depletion of Purkinje cells was not prevented. 13 However, in BALB/c mice with cholesterol-storage diseases, transplantation of fetal liver cells corrects accumulation of lipids in tissues and prevents fatal neuropathy. Tremors disappeared and normal weight was almost regained. Deposition of lipids in tissues was decreased, neuropathy was prevented, and survival was significantly prolonged. 14 Nevertheless, liver transplantation in a 7-year-old girl with Niemann-Pick type C disease and liver cirrhosis was successful in restoring hepatic function but failed to slow down neurologic progression. 15 The results of BMT in our patient were similar to the C57BL/KsJ spm/spm mouse receiving BMT. Acute accelerated then continuous neurological deterioration was noted after BMT. Acute accelerated neurological deterioration may be due to a side-effect of busulfan. MRI shows obvious atrophic changes of the brain 1/2 month before and 6 months after BMT (Figure 2a and b) and provides evidence for the failure of BMT to prevent CNS deterioration. However, long-term CNS follow-up will still be undertaken in this patient. In addition, rectal biopsy will also be considered in this patient and other new cases, since it may allow insight into the effects of the engrafted normal marrow on ganglion cells as neuronal storage also occurs in the Schwann's cells and axons. 16 Over the decade, BMT has been used to treat many storage diseases including adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy, Gaucher's disease and Hurler syndrome, etc. Engraftment and the resulting enzymatic reconstitution are concordant, and positive changes occur in the central nervous system (CNS) following long-term engraftment. After engraftment, significant improvement in the clinical course of each of these diseases occurs. Earlier diagnosis will allow BMT to be performed in the presymptomatic stage, providing enhancement of the positive effects of such treatment. 17 It is not clear whether in NPC it will be helpful if BMT is performed earlier, before the symptomatic stage.
In this report, we have shown that a correction occurred in the liver, spleen, bone marrow and lung following successful engraftment in human NPC. Such a therapeutic response is remarkable since the underlying hypothesis is that of a membrane receptor problem for cholesterol. This positive response may be directly due to the replacement of foamy histiocytes in the viscera with donor cells, but cross-correction in the integral membrane protein defect by BMT is still a possibility. In vitro studies have revealed that NPC1/NPC2 somatic cell hybrids exhibit a normal phenotype. Suprisingly, co-cultivation of NPC1 and NPC2 fibroblasts also corrects the phenotype 18 to a small degree. It is possible that a soluble factor which enhances cholesterol esterification in NPC-1 fibroblasts is released into the medium by NPC-2 cells or exchanged by cellular junctions, or perhaps a correcting factor is secreted, which acts downstream of NPC1. 19 Although the BMT result in this case is not encouraging, diagnosis in fetal life in families where an older sibling is affected or by clinical judgement (prolonged cholestatic jaundice in newborn period) may allow an immediate postnatal transplant or other interventions before the symptomatic stage. Earlier diagnosis and intervention are important and are most likely to provide an answer concerning whether or not neurologic disease can be prevented.
